Biotech funding recovery could lift CRO spending by 40%+ for small biotechs

On June 17, 2026, Morgan Stanley issued a pair of starkly divergent calls that reframed the investment narrative for the two leading contract research organizations (CROs): Charles River Laboratories (CRL) and IQVIA Holdings (IQV). In a coordinated set of notes, the bank upgraded Charles River to Overweight and downgraded IQVIA to Equal-weight, while simultaneously adjusting price targets—CRL's target rising to $220 from $185, and IQVIA's falling to $200 from $225. The twist is that these two companies are directly linked by an asset transaction: IQVIA is in the process of acquiring European lab assets that Charles River had previously agreed to sell, a deal that underscores the reshuffling underway in the drug research services industry. Morgan Stanley's rationale centers on the recovery in biopharma funding. As early-stage biotech and small drugmakers raise more capital, demand for outsourced laboratory testing and research services increases. Charles River, which derives 40% to 45% of its revenue from small and mid-sized biotech clients—more than double IQVIA's exposure—stands to benefit disproportionately. The bank's bullish CRL thesis also draws on the company's recent strategic streamlining: divestiture of its CDMO and Cell Solutions units, and the pending sale of European lab assets, which have sharpened its focus on core drug research testing. In contrast, IQVIA’s downgrade reflects valuation concerns rather than operational weakness. Although IQVIA reported revenue growth of 8.4% in its most recent quarter, the stock's premium multiple relative to peers leaves limited upside as the market rotates toward companies with higher beta to the biotech funding cycle. The call is not a repudiation of IQVIA’s business model—its data capabilities, technology platform, and scale with large pharma remain formidable—but a view that the stock is fairly valued for the current environment. This split decision provides a microcosm of broader forces reshaping the CRO landscape. After a period of capital scarcity that pressured demand for outsourced research, a rebound in venture financing and IPO activity is funneling capital into smaller drug developers. Companies that are over-indexed to this segment, like Charles River, are poised to capture a meaningful revenue tailwind. The market is also rewarding firms that have taken proactive steps to optimize their portfolios. Charles River’s Q1 2026 results—revenue of $995.8 million and non-GAAP earnings of $2.06 per share, beating consensus—already showed early signs of a turn, lending credibility to the upgrade. For IQVIA, the challenge is to demonstrate that its diversified model, including its market-leading real-world data and analytics unit, can sustain growth without the valuation compression that often follows a market sentiment shift. The asset purchase from Charles River may ultimately prove accretive, but the market is likely to reserve judgment until integration milestones are met. Looking ahead, investor attention will focus on the pace of biotech funding over the remainder of 2026. A sustained reopening of the capital markets would validate Morgan Stanley’s call on CRL, while any stall would make IQVIA’s defensive characteristics more attractive. The CRO sector is thus becoming a lens through which broader healthcare investment trends can be assessed. For stakeholders across the pharmaceutical ecosystem, the signal is clear: the funding environment is tilting, and the winners will be those best positioned to capture the new flow of discovery-stage spending.